Prucalopride is a selective 5-hydroxytryptamine type 4 (5-HT 4 ) receptor agonist developed for the treatment of gastrointestinal disorders. The endogenous agonist 5-HT acting via 5-HT 4 receptors increases the L-type Ca 2ϩ current
Activation of 5-hydroxytryptamine type 4 (5-HT 4 ) receptors may have multiple functional roles in the human body, including inotropic effects in the atrium, prokinetic activity in the gastrointestinal tract, and involvement in memory and learning processes in the brain (Eglen et al., 1995; Hegde and Eglen, 1996) . Moreover, 5-HT 4 receptors have been implicated in various pathological conditions including atrial arrhythmias (Kaumann, 1994) , neurodegenerative diseases (Wong et al., 1996) , and gastrointestinal motility disorders (Talley, 1992) . Consequently, 5-HT 4 receptors have been a target for the development of novel 5-HT 4 agonists (e.g., to treat functional bowel disorders (Talley, 2001) and antagonists (e.g., to treat atrial fibrillation; Kaumann, 1994) .
In human atrium, 5-HT 4 receptors are the only subtype present (Kaumann et al., 1990; Blondel et al., 1997) , and activation with 5-HT increases the amplitude of the L-type Ca 2ϩ current (I CaL ) via the cyclic AMP-dependent cascade (Ouadid et al., 1992) . Proarrhythmic activity of 5-HT has been demonstrated previously in human atrial muscle (Kaumann and Sanders, 1994) and in human atrial myocytes (Pau et al., 2003) , probably associated with the increased I CaL . Moreover, it has been postulated that the release of 5-HT from platelets may be involved in the origin and maintenance of atrial fibrillation (Kaumann, 1994) . In a pig model of atrial fibrillation, a 5-HT 4 antagonist, RS-100302, has been reported to be antiarrhythmic by prolonging the effective refractory period (Rahme et al., 1999) , suggesting that endogenously released 5-HT may shorten the effective refractory period, thereby sustaining re-entry circuits. For these reasons, there has been concern that 5-HT 4 receptor agonists when used as gastrokinetic agents in humans may generate atrial arrhythmias via intracellular Ca 2ϩ overload and/or a reduced refractoriness (Tonini et al., 1999; Yusuf et al., 2003) .
Prucalopride, a novel 5-HT 4 receptor agonist with a benzofurancarboxamide structure, is currently under investigation for the treatment of idiopathic chronic constipation (Coremans et al., 2003) . It has been demonstrated to be a potent and specific 5-HT 4 receptor agonist in studies on human native and recombinant 5-HT 4 receptor subtypes (Prins et al., 2000; Briejer et al., 2001; Pindon et al., 2002) . There has been only one previous study on the effects of prucalopride on cardiac ion currents, specifically the rapid component of the recombinant delayed rectifier K ϩ current (I Kr ) encoded by the cloned human ether-a-go-go-related gene (HERG) (Potet et al., 2001 ). This study showed that micromolar concentrations of prucalopride significantly blocked I Kr . Although I Kr is present in the human ventricle , in the human atrium it is not clear whether I Kr may play a substantial role in action potential repolarization (Wang et al., 1994; Lee and Lee, 1998; Bertaso et al., 2002) . The electrophysiological effects of prucalopride have not yet been studied in human atrium.
The aims of this study were to assess in human atrial myocytes the electrophysiological effects of prucalopride on I CaL , action potential duration (APD), cellular effective refractory period (ERP), and arrhythmic activity; and to compare the effects of prucalopride with those of the endogenous agonist 5-HT.
Materials and Methods
Tissue and Cell Isolation. Procedures for obtaining human tissue were approved by the institutional ethics committee of Glasgow Royal Infirmary and conform to the Declaration of Helsinki (World Medical Association, 1997) . Samples of the right atrial appendage were obtained from consenting patients undergoing cardiac surgery. All patients had received prior therapy with ␤-adrenoceptor antagonists. Atrial cells were isolated enzymatically using a method described in detail by Workman et al. (2001) .
Electrical Recording Techniques. The whole-cell perforated patch-clamp technique was used to record action potentials and calcium currents, as described in detail by Pau et al. (2003) . Briefly, cells were superfused at 37°C with a physiological solution containing: 130.0 mM NaCl, 4.0 mM KCl, 2.0 mM CaCl 2 , 1.0 mM MgCl 2 , 10.0 mM glucose, and 10.0 mM HEPES, pH 7.4. To record calcium currents, electrodes were filled with a solution containing: 30.0 mM CsCl, 5.0 mM HEPES, 1.0 mM MgCl 2 , 100.0 mM Cs methanesulfonic acid, and 5.0 mM NaCl. To record action potentials, an internal solution containing 30.0 mM KCl, 5.0 mM HEPES, 1.0 mM MgCl 2 , 100.0 mM K methanesulfonic acid, and 5.0 mM NaCl was used. The series resistance was observed to stabilize between 5 and 15 min at 9.9 Ϯ 0.3 M⍀ (n ϭ 96 cells), with a mean cell capacity of 78 Ϯ 2 pF. Capacitative transients were compensated electronically from the recordings, and the voltage drop across the series resistance was also compensated (68 -80%). The software program WinWCP (J. Dempster, University of Strathclyde, Glasgow, UK) was used both to stimulate and record electrical activity. All currents were normalized to the cell's capacity.
Experimental Protocols. Voltage clamp was used to record I CaL . The voltage dependence of this current was measured from a holding potential of Ϫ40 mV, increasing in steps of 10 mV, up to ϩ40 mV, with pulses of 250-ms duration (0.33 Hz). The time-dependent effect of drugs on peak I CaL was measured with pulses of 250-ms duration, from Ϫ40 to ϩ 10 mV (0.2 Hz).
Current clamp was used to record actions potentials and the cellular effective refractory period at the physiological rate of 75 beats/min (bpm) using 5-ms stimulating pulses of 1.2ϫ threshold strength. The ERP was measured using a standard S 1 -S 2 stimulation protocol and was defined as the longest S 1 -S 2 interval that failed to elicit an S 2 action potential of amplitude Ͼ80% of the preceding S 1 action potential. The APD was calculated as the interval between the action potential upstroke and repolarization to the level of 50% (APD 50 ), 75% (APD 75 ), and 90% (APD 90 ) of the upstroke amplitude. I CaL , action potentials, and the ERP were recorded before, and 90 s after, drug additions and again 180 s after removal of drugs.
Drugs. Prucalopride (R093877; Briejer et al., 2001 ) and the specific 5-HT 4 antagonist GR-113808 (Kaumann, 1993) were donated by Johnson and Johnson Pharmaceutical Research and Development (Beerse, Belgium) and were dissolved in dimethyl sulfoxide with a stock solution of 10 mM and subsequently diluted in physiological solutions. 5-HT (Sigma-Aldrich, St. Louis, MO) was made up as a 10 mM stock solution in distilled water.
Data Analysis and Statistics. Clinical characteristics and drug treatments of each patient were obtained from the case notes. Only patients in sinus rhythm at the time of surgery were included. Cells were excluded from analysis if either the APD 50 or peak I CaL decreased irreversibly during the protocol. Concentration-response data for the effect of prucalopride on I CaL were fitted iteratively (Prism 3.0; GraphPad Software Inc., San Diego, CA) using a variable slope sigmoidal concentration-response curve (Hill equation). The curves were fitted to mean I CaL values, obtained at six concentrations of prucalopride between 1 nM and 100 M. The concentrationresponse curve for 5-HT was obtained previously in our lab (Pau et al., 2003) . Curve-fit values were compared using a two-tailed unpaired Student's t test. Time-dependent inactivation of I CaL was fitted by a biexponential function using the WCP software program and was defined by the following equation: I CaL (t) ϭ A 1 .exp(Ϫt/ 1 ) ϩ A 2 .exp(Ϫt/ 2 ) ϩ C, where A 1 , A 2 , 1 , and 2 are the amplitudes and decay time constants of the respective exponential components, and C is the steady-state amplitude. Data are expressed as mean Ϯ S.E.M., with n being equal to the number of cells studied. Mean values were compared using two-tailed paired or unpaired Student's t tests, as appropriate. A Fisher's exact test was used to assess the level of significance of differences in the incidences of arrhythmic activity between drugs. p Ͻ 0.05 was regarded as statistically significant.
Results
Patients' Clinical Characteristics. All patients were undergoing coronary artery bypass graft surgery, were taking ␤-adrenoceptor antagonists, suffered from angina, and none had severe left ventricular dysfunction (Table 1) . Eighty-two percent of the patients were also treated with an angiotensin-converting enzyme inhibitor and 36% of the patients with a calcium channel blocker. ␤-Adrenoceptor antagonists had been administered for more than 10 days prior to surgery. No patient was administered sotalol (a ␤-blocker with additional class III antiarrhythmic activity). Patients received their routine cardiac drugs on the day of surgery. Mean heart rate was 58 Ϯ 2 bpm (n ϭ 11).
Effects of Prucalopride, 5-HT, and GR-113808 on I CaL in Human Atrial Cells. Prucalopride produced a significant increase in the amplitude of I CaL , as shown in Fig. 1 by the I CaL current density-voltage relationships. An example of original I CaL recordings is also shown (Fig. 1, inset) . Prucalopride (10 M) increased the mean magnitude of peak I CaL (recorded at ϩ10 mV) from Ϫ5.7 Ϯ 0.7 pA/pF to Ϫ10.2 Ϯ 1.6 pA/pF (p Ͻ 0.05, n ϭ 10 cells, 7 patients). This increase in peak I CaL occurred without any change in the voltage dependence of the current and was reversible on washout of prucalopride (Ϫ5.7 Ϯ 1.1 pA/pF; n ϭ 7 cells, 5 patients).
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The time course of change in I CaL by prucalopride and its blockade by the specific 5-HT 4 receptor antagonist, GR-113808, can be seen in Fig. 2 . Prucalopride at 10 M caused a stable increase in I CaL , which was completely antagonized by GR-113808 at 1 M (n ϭ 5 cells, 3 patients). This increase, from a control value of Ϫ5.9 Ϯ 1.2 to Ϫ13.1 Ϯ 3.8 pA/pF, was abolished by GR-113808 to Ϫ5.4 Ϯ 1.2 pA/pF (p Ͻ 0.05). The effect of this antagonist was partially reversible upon its washout (to 6.5 Ϯ 1.1 pA/pF). Figure 3A shows that the increase in I CaL with prucalopride (10 M) was less than that produced by 5-HT (10 M) in the same cell. This was confirmed by mean data. Prucalopride increased I CaL from Ϫ5.5 Ϯ 0.8 to Ϫ10.5 Ϯ 1.7 pA/pF (p Ͻ 0.05, n ϭ 16 cells, 9 patients). Subsequent superfusion of 5-HT alone, in the same cells, increased I CaL further, to Ϫ17.7 Ϯ 2.8 pA/pF (p Ͻ 0.05). The percentage increase in I CaL produced by 5-HT (233 Ϯ 26% compared with control) was significantly greater than that produced by prucalopride (89 Ϯ 15%; p Ͻ 0.05) (Fig. 3B) . The time-dependent inactivation of I CaL was unchanged by the application of prucalopride (10 M) or 5-HT (10 M). The fast ( 1 ) and the slow ( 2 ) inactivation time constants of basal I CaL were 4.4 Ϯ 0.3 and 47.7 Ϯ 8.1 ms, respectively, and were not significantly different in the presence of prucalopride ( 1 ϭ 6.0 Ϯ 1.8 ms and 2 ϭ 41.9 Ϯ 6.2 ms) or 5-HT ( 1 ϭ 5.6 Ϯ 1.8 ms and 2 ϭ 40.0 Ϯ 5.1 ms). The respective fractions of the fast (A 1 ϭ 72.5 Ϯ 1.9%) and slow (A 2 ϭ 27.5 Ϯ 1.9%) components of the I CaL inactivation amplitude remained unchanged by the application of either prucalopride or 5-HT.
The Concentration-Response Relationship of the Effect of Prucalopride on I CaL . The concentration-response curve of the effect of prucalopride on peak I CaL obtained in atrial cells from patients with prior ␤-adrenoceptor antagonists treatment is shown in Fig. 4 . This figure also shows the superimposed concentration-response curve of the effect of 5-HT on peak I CaL obtained previously in our lab in atrial cells from a similar group of patients (Pau et al., 2003) . Prucalopride (from 1 nM to 100 M) elicited a concentrationdependent increase in the amplitude of peak I CaL (measured at ϩ10 mV), with a maximum response (E max ) equal to an increase of 93 Ϯ 14% above control (n ϭ 7-22 cells, 2-9 patients). This was significantly less than that produced by the maximum response of 5-HT (E max ϭ 299 Ϯ 12% above control; p Ͻ 0.05). However, there were no significant differences between prucalopride and 5-HT for either the log EC 50 (Ϫ6.66 Ϯ 0.44 versus Ϫ7.09 Ϯ 0.07, respectively) or the Hill coefficient, n H (0.76 Ϯ 0.46 versus 1.46 Ϯ 0.56, respectively).
Effect of Prucalopride and 5-HT on Action Potentials and the Refractory Period. Fig. 5 shows representative traces of action potentials and measurements of ERP illustrating the effects of 10 M prucalopride (Fig. 5B) or 5-HT (Fig. 5C ), compared with control conditions (Fig. 5A) . Prucalopride (10 M) caused a small but significant prolongation in the APD 50 from 12 Ϯ 2 to 17 Ϯ 3 ms (p Ͻ 0.05; n ϭ 22 cells, 9 patients), representing an increase of 6 Ϯ 2 ms (p Ͻ 0.05). This effect was fully reversible upon washout of prucalopride (12 Ϯ 3 ms; n ϭ 13 cells, 8 patients). There was no significant or reversible effect of prucalopride on the APD 75 (141 Ϯ 12 versus 146 Ϯ 11 ms), APD 90 (237 Ϯ 18 versus 236 Ϯ 18 ms), or ERP (224 Ϯ 25 versus 232 Ϯ 28 ms).
In 11 of the 22 cells (from 8 patients) studied with prucalopride, we investigated the effects of 5-HT at 10 M following 3-min washout of prucalopride at 10 M. As shown in Fig.  6A , the prolongation of the APD 50 produced by 5-HT, from a control value of 14 Ϯ 3 to 32 Ϯ 7 ms (p Ͻ 0.05), was greater than the prolongation produced by prucalopride (12 Ϯ 2 to 19 Ϯ 5 ms; p Ͻ 0.05), in these cells. The mean duration by which the APD 50 was increased was also greater with 5-HT (18 Ϯ 5 ms) compared with that with prucalopride (7 Ϯ 3 ms; p Ͻ 0.05). The effect of 5-HT was fully reversible after 3-min washout (15 Ϯ 4 ms; n ϭ 7 cells, 6 patients). 5-HT did not significantly affect the APD 75 , APD 90 or the ERP, consistent with our previous report (Pau et al., 2003) . Figure 6B shows that the calcium channel blocker nifedipine at 10 M prevented the prucalopride and the 5-HT-induced increases in APD 50 in the 11 (5 patients) and 4 (2 patients) cells studied, respectively. This concentration of nifedipine had been shown to markedly reduce I CaL from Ϫ4.8 Ϯ 0.8 to Ϫ0.2 Ϯ 0.1 pA/pF (p Ͻ 0.05; n ϭ 5 cells, 4 patients). 
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Effects of Prucalopride and 5-HT on Arrhythmic Activity in Human Atrial Cells. Abnormal depolarizations were not observed in any of the 22 cells to which 10 M prucalopride was applied. In contrast, when 10 M 5-HT was subsequently applied (to 11 of these), abnormal depolarizations occurred in 3 (27%) of the cells studied (p Ͻ 0.05). Figure 7 shows an example of abnormal depolarizations caused by 5-HT, but not by prucalopride, and their abolition by GR-113808 at 1 M. In another cell, from a different patient, 5-HT induced abnormal depolarizations in the absence, but not in the presence, of nifedipine at 10 M (not shown).
Discussion
This study has demonstrated, for the first time to our knowledge, that prucalopride in human atrial cells acted as a partial rather than full agonist on the L-type calcium current and action potential early repolarization via 5-HT 4 receptors. Similarly to 5-HT, prucalopride lacked effects on the late phase of the atrial action potential repolarization and the effective refractory period. Unlike 5-HT, prucalopride did not induce abnormal depolarizations.
Prucalopride has been shown previously to be a full agonist in several areas of the human body including the gastrointestinal (Prins et al., 2000) and central nervous (Robert et al., 2001) systems. Studies using either native or recombinant 5-HT 4 receptors have shown that prucalopride had similar, or even greater, efficacy than the endogenous agonist 5-HT (Prins et al., 2000; Pindon et al., 2002; Lezoualc'h and Robert, 2003) . The EC 50 value for prucalopride in human atrial cells in the present study was higher than that obtained with human recombinant 5-HT 4a and 5-HT 4b receptor isoforms (Briejer et al., 2001; Pindon et al., 2002) , which indicated a lower potency of the agonist in human atrial cells. In this study, we included only patients who had been previously treated with ␤-adrenoceptors antagonists. Such prior therapy did not affect the mRNA expression of 5-HT 4 receptors and L-type Ca 2ϩ channels subunits ␣ 1c , ␣ 2 /␦ 1 , ␤ 1a , ␤ 1b , and ␤ 1c in the human atrium (Grammer et al., 2001 ). However, we have previously shown in human atrial cells that prior ␤-blockade enhanced the maximal response of I CaL to 5-HT but with no effect on the EC 50 or the Hill coefficient of the concentration-response curve for 5-HT (Pau et al., 2003) . Hence, our finding of lower potency remains relevant to patients who have not been receiving ␤-adrenoceptor antagonists.
To date, nine 5-HT 4 receptor subtypes (5-HT 4a-i/hb/n ) have been identified and localized in the human body (Langlois and Fischmeister, 2003; Brattelid et al., 2004) , but only some of these (5-HT 4a-c , 5-HT 4g , 5-HT 4i , and 5-HT 4n ) have been shown to be present in the human atrium (Bach et al., 2001; Medhurst et al., 2001; Vilaró et al., 2002; Brattelid et al., 2004) . In addition, the pharmacological properties of the 5-HT 4 isoforms have been associated with different receptor levels of expression (Bach et al., 2001; Medhurst et al., 2001; Vilaró et al., 2002; Brattelid et al., 2004) . Thus, it is possible that prucalopride acts as partial agonist with low potency in human atrial cells because of the expression of specific 5-HT 4 isoforms and/or because of the different levels of expression of these isoforms present in the human atrium, compared with other tissues. In addition, 5-HT and prucalopride, acting via 5-HT 4 receptors, may differently affect the signal transduction cascade, including the phosphorylation of different isoforms of the L-type Ca 2ϩ channel (Pindon et al., 2002) . These questions may be resolved following the development of more selective agonists, antagonists, and antibodies acting on specific 5-HT 4 receptor subtypes or by coexpressing the L-type Ca 2ϩ channels with the recombinant 5-HT 4 receptors isoforms in a 5-HT receptor-free cell model.
Prucalopride significantly prolonged the early repolarization phase of the action potential without affecting the late phase or the refractory period, likely due to the observed increase in I CaL . This was confirmed by the experiments using the calcium channel blocker, nifedipine, which abolished the effects of prucalopride and 5-HT on the action potential. In addition, prucalopride had a less marked action to prolong APD 50 than did 5-HT (at maximally effective concentrations), consistent with the partial activity observed on I CaL . However, we cannot exclude effects on other currents of importance during repolarization in the human atrium, such as the transient outward K ϩ current, I TO , and the ultra-rapid component of the delayed rectifier K ϩ current, I Kur . The fact that a 5-HT 4 antagonist, RS-100302, prolonged the ERP in an in vivo pig model of atrial fibrillation (Rahme et al., 1999) suggested that 5-HT 4 agonists may shorten the ERP and, therefore, be pro-arrhythmic by reducing the minimum path length required for re-entry. However, this is not supported by our experiments in isolated human atrial cells, in which neither prucalopride nor 5-HT abbreviated the late phase of repolarization or the refractory period. It is noteworthy that in canine atrial cells isolated using the chunk method, the repolarizing, delayed rectifier K ϩ current was recorded in significantly fewer cells than in those isolated by enzyme perfusion . Also, it has been reported that, in the human atrium, this current is limited to only a subpopulation of cells (Wang et al., 1994) or even absent (Lee and Lee, 1998; Bertaso et al., 2002) . These two factors may explain the lack of effect of prucalopride and 5-HT to shorten late repolarization and refractory period in human atrial myocytes. Alternatively, in the pig, the 5-HT 4 antagonist, RS-100302, may have had a direct effect, independently of blocking 5-HT receptors to prolong ERP.
In the present study, we investigated the effects on I CaL of a range of concentrations of prucalopride, from 1 nM to 100 M, to obtain a full concentration-response relationship of the drug. For comparison, the effective therapeutic range of prucalopride in humans has been found to be between 1 and 10 nM with a mean plasma concentration of around 2 ng/ml (ϳ5 nM) after a 4-week treatment period and with a half-life of prucalopride around 24 h (Emmanuel et al., 2002) . Therefore, the concentration of 10 M used here to investigate the effects of prucalopride on action potentials, refractoriness, and arrhythmic activity was 1000-fold higher than its normal therapeutic concentration in humans. Nevertheless, despite using atrial cells from patients with prior treatment with ␤-adrenoceptor antagonists, which has been shown to increase the incidence of 5-HT-induced arrhythmic contrac- 
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at ASPET Journals on September 6, 2017 jpet.aspetjournals.org tions (Sanders et al., 1995) and abnormal depolarizations (Pau et al., 2003) , we have shown that 10 M prucalopride did not induce abnormal depolarizations in any of the atrial cells studied. In contrast, 10 M 5-HT, after perfusion with 10 M prucalopride, induced abnormal depolarizations in ϳ27% of the cells studied, which is also consistent with our previous observations in human atrial myocytes (Pau et al., 2003) . It is noteworthy that in the study by Sanders et al. (1995) , the partial 5-HT 4 agonist, renzapride, was not reported to produce arrhythmic contractions in human atrial cells, whereas 5-HT produced such contractions in human atrial cells and strips. In the present study, it is likely that prucalopride lacked arrhythmogenic activity because it acts as a partial rather than a full agonist and caused a significantly smaller increase in I CaL and calcium loading than did 5-HT.
There is major concern about the potential for ventricular arrhythmias when using 5-HT 4 receptor agonists as gastrokinetic agents (Tonini et al., 1999; Yusuf et al., 2003) . This is related to the ability of several drugs, including the enterokinetic cisapride, to block I Kr, with associated prolongation of the repolarization phase of the ventricular action potential that underlies the acquired long QT syndrome (Viskin, 1999) . The only report of effects of prucalopride on I Kr encoded by cardiac HERG demonstrated that at micromolar concentrations, prucalopride significantly blocked HERG current expressed in a kidney cell line (Potet et al., 2001) . However, at therapeutic concentrations, prucalopride had no effect on the QT interval in humans (De Schryver et al., 2002; Krogh et al., 2002) , consistent with a lack of effect of prucalopride on human ventricular I Kr . The present findings in human atrial myocytes of a lack of effect of prucalopride on late repolarization and refractoriness are also consistent with an absence of effect on atrial delayed rectifier K ϩ current. An additional mechanism by which prucalopride might affect action potential duration would be by influencing the time course of inactivation of I CaL , as well as its peak density, but we demonstrated here that prucalopride and 5-HT had no effects on I CaL inactivation in human atrial cells.
In conclusion, these data indicate that, in the human atrium, the prucalopride-induced increase in calcium current was associated with prolongation of the early phase of action potential repolarization but not late repolarization, refractoriness, or arrhythmic activity. Moreover, prucalopride, when compared with 5-HT, behaved as a partial rather than full agonist in enhancing I CaL and APD 50 in human atrial myocytes. These results further support the hypothesis that the expression of specific 5-HT 4 receptor subtypes in human atrial cells may mediate different functional electrophysiological responses to different agonists, and this needs to be taken into account when using 5-HT 4 agonists in humans.
